loncastuximab tesirine sold brand name zynlonta monoclonal antibody conjugate medication used treat large bcell lymphoma highgrade bcell antibodydrug conjugate adc composed humanized antibody targeting protein common side effects include increased levels gammaglutamyltransferase ggt liver enzyme neutropenia low levels neutrophils type white blood cell tiredness anemia low levels red blood cells thrombocytopenia low levels blood platelets nausea feeling sick peripheral edema swelling due fluid retention especially ankles feet loncastuximab tesirine approved medical use united states april european union december us food drug administration fda considers firstinclass loncastuximab tesirine indicated treatment adults relapsed refractory large bcell lymphoma highgrade bcell humanized monoclonal antibody stochastically conjugated via valinealanine cleavable maleimide linker cytotoxic anticancer pyrrolobenzodiazepine pbd dimermedical citation needed antibody binds protein highly expressed surface bcell hematological including certain forms lymphomas leukemiasmedical citation needed binding tumor cells antibody internalized cytotoxic drug pbd released cancer cells killedmedical citation needed pbd dimers generated pbd monomers class natural products produced various actinomycetes pbd dimers work crosslinking specific sites dna blocking cancer cells division cause cells diemedical citation needed class dnacrosslinking agents significantly potent systemic chemotherapeutic benefit side effects loncastuximab tesirine evaluated one clinical trial included participants relapsed refractory diffuse large bcell lymphoma least two prior treatments work longer participants received loncastuximab tesirine mgkg every weeks treatment cycles mgkg every weeks subsequent treatment loncastuximab tesirine treatment continued either disease worsened participants experienced unacceptable side effects benefit loncastuximab tesirine evaluated measuring many participants complete partial tumor shrinkage response long response participants clinical trial also evaluated side effects purpose drug trials conducted sites united states united kingdom italy loncastuximab tesirine granted orphan drug designation fda treatment diffuse large bcell loncastuximab tesirine approved fdas accelerated approval september committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product zynlonta intended treatment adults diffuse large bcell lymphoma dlbcl highgrade bcell lymphoma applicant medicinal product adc therapeutics nl loncastuximab tesirine approved medical use european union december given mechanism action loncastuximab tesirine may appealing patients ineligible cart cell httpsenwikipediaorgwikiloncastuximabtesirine